News

Published on 17 May 2022 on Benzinga via Yahoo Finance

Sorrento Starts Mid-Stage Study Of Abivertinib In Prostate Cancer


Article preview image

The FDA has signed off Sorrento Therapeutics Inc's (NASDAQ: SRNE) investigational new drug application (IND) for Abivertinib (Fujovee) for Phase 2 MAVERICK study in metastatic castrate-resistant prostate cancer (mCRPC).The MAVERICK study will be conducted in a partnership with the Prostate Cancer Clinical Trials Consortium and will enroll participants with both abiraterone-naïve and abiraterone-progressing mCRPC.The MAVERICK trial will be conducted as an open-label study of Abivertinib with abiraterone in up to 100 participants harboring the adrenal-permissive HSD3β1 allele (heterozygous or homozygous).The study's primary objective is to evaluate the efficacy of Abivertinib with abiraterone for 6-month radiographic progression-free survival (rPFS).The primary endpoint is the 6-month rPFS.Sorrento Therapeutics' partner, China Oncology Focus Limited, a subsidiary of Lee's Pharmaceutical Holdings Limited, has completed the patient enrollment for a Phase 3 trial of socazolimab in extensive-stage small-cell lung cancer.A total of 498 patients have been enrolled in the study. An interim analysis is expected to be conducted in April 2023.Price Action: SRNE shares are up 8.68% at $1.57 during the market session on the last check Tuesday.

See more from Benzinga

NASDAQ.SRNE price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Is a Surprise Coming for Sorrento Therapeutics (SRNEQ) This Earnings Season?

Investors are always looking for stocks that are poised to beat at earnings season and Sorrento T...

Zacks via Yahoo Finance 2 Mar 2023

Bankrupt Sorrento Therapeutics Secures Court Approval for $75M Financing

Sorrento Therapeutics Inc (NASDAQ: SRNE) announced that the U.S. Bankruptcy Court for the Souther...

Benzinga via Yahoo Finance 22 Feb 2023

An Update On Sorrento: Hitting Rock Bottom And Finding A Shovel (NASDAQ:SCLX)

One should note that Sorrento Therapeutics has been involved in multiple legal actions with Dr....

Seeking Alpha 22 Feb 2023

Why Frequency Therapeutics Are Trading Lower By 82%? Here Are Other Stocks Moving In Monday's...

Why Frequency Therapeutics Are Trading Lower By 82%? Here Are Other Stocks Moving In Monday's...

Investing.com 13 Feb 2023

Sorrento Therapeutics Stock Nosedives After Filing Bankruptcy Paperwork

COVID-19 drug and vaccine developer Sorrento Therapeutics Inc (NASDAQ: SRNE) is filing for bankru...

Benzinga via Yahoo Finance 13 Feb 2023

Sorrento Therapeutics Files for Bankruptcy to Halt $173 Million Licensing Judgments

The biopharmaceutical company filed for chapter 11 to halt the collection of judgments by affilia...

The Wall Street Journal 13 Feb 2023

U.S. shares higher at close of trade; Dow Jones Industrial Average up 1.11%

U.S. shares higher at close of trade; Dow Jones Industrial Average up 1.11%

Investing.com 13 Feb 2023

U.S. shares higher at close of trade; Dow Jones Industrial Average up 1.11%

U.S. shares higher at close of trade; Dow Jones Industrial Average up 1.11%

Investing.com 13 Feb 2023

ImmunityBio: Upcoming PDUFA, Solid Data, Confusing Finances (NASDAQ:IBRX)

ImmunityBio, Inc. (NASDAQ:IBRX) is another Patrick Soon-Shiong company, one of the relatively mor...

Seeking Alpha 6 Jan 2023

Sorrento Touts Positive Early-Stage Trial Data From Oral COVID-19 Therapy

Sorrento Therapeutics Inc (NASDAQ: SRNE) released topline Phase 2 SAD/MAD study data of its oral ...

Benzinga via Yahoo Finance 30 Nov 2022